DIA Europe 2024

Europeans are facing decreased access to new medicines and the ability to take part in ground-breaking clinical trials, as research and development of new treatments increasingly moves to more ambitious life science sectors in the US and Asia: • R&D investment: In 2002 the US spent $2billion more than Europe on R&D; today that figure is $25billion - a rise of 1000%. Of the total R&D investments made in the US, Europe, China and Japan, only 31% of this occurs in Europe. This has declined steadily from 41% in 2001. China has meanwhile grown its share from 1% to 8%. • ATMPs: Clinical trial activity is twice as high in the US and almost three times as high in China than in Europe. The number of ATMP trials conducted in the US and Asia-Pacific region grew by 70% and 67%, respectively from 2014-21, while Europe remained stagnant. • Clinical trials: Europe accounted for a 19.3% share of global clinical trials activity in 2020, a decrease of 6.3%, compared with a 25.6% average over the last ten-years. Decisions regarding investment in research hubs and manufacturing are long-term decisions, while clinical trials are often carried out over many years. For Europe to be strategically autonomous from the rest of the world it requires a vibrant R&D ecosystem. The policy decisions taken today will impact on Europe’s attractiveness for investment for decades to come. The session will bring together key players in the pharmaceutical innovation from investors, developers, health and regulatory authorities, patients to discuss Europe’s ambition for pharmaceutical innovation, components of a successful innovation environment, and how to create it in Europe using the momentum of the pharmaceutical strategy.